Treatment response to a second or third TNF-inhibitor in RA: Results from the South Swedish Arthritis Treatment Group Register

Rheumatology

Volumn 47, Issue 4, 2008, Pages 507-513

  Karlsson, J A ^a   Kristensen, L E ^a   Kapetanovic, M C ^a   Gulfe A ^a   Saxne, T ^a   Geborek, Pierre ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anti TNF; Observational study; Predictors; RA; Switching

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ACTIVITY; DOSE RESPONSE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT SELECTION; PRIORITY JOURNAL; REGISTER; REMISSION; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; SWEDEN; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; AGED; CLINICAL TRIAL; DRUG ANTAGONISM; FOLLOW UP; HOSPITALIZATION; MIDDLE AGED; MULTICENTER STUDY; PROGNOSIS; PROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 43049162899     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken034     Document Type: Article

References (44)

1. Moreland LW, Schiff MH, Baumgartner SW et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
2. Bathon JM, Martin RW, Fleischmann RM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
3. Keystone EC, Schiff MH, Kremer JM et al. Once-weekly administration of 50mg etanercept in patients with active rheumatoid arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50:353-63.
4. Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
5. Lipsky PE, van der Heijde DM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
6. Weisman MH, Moreland LW, Furst DE et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study. Clin Ther 2003;25:1700-21.
7. Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003;48:35-45.
8. Keystone EC, Kavanaugh AF, Sharp JT et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11.
9. Combe B. Switching between anti-TNFα agents: What is the evidence? Joint Bone Spine 2004;71:169-71.
10. Shergy WJ, Phillips RM Jr, Hunt RE, Hernandez J. Safety and efficacy of infliximab therapy after etanercept failure: A case series [abstract]. Arthritis Rheum 2001;44(Suppl):S81.
11. van Vollenhoven R, Harju A, Brannemark S, Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis 2003;62:1195-8.
12. Ang HT, Helfgott S. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis? J Rheumatol 2003;30:2315-8.
13. Yazici Y, Erkan D. Do etanercept-naive patients with rheumatoid arthritis respond better to infliximab than patients for whom etanercept has failed? [letter]. Ann Rheum Dis 2004;63:607-8.
14. Gomez-Puerta JA, Sanmarti R, Rodriguez-Cros JR, Canete JD. Etanercept is effective in patients with rheumatoid arthritis with no response to infliximab therapy [letter]. Ann Rheum Dis 2004;63:896.
15. Favalli EG, Arreghini M, Arnoldi C et al. Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis [letter]. Arthritis Rheum 2004;51:301-2.
16. Brocq O, Albert C, Roux C, Gerard D, Breuil V, Ziegler LE. Adalimumab in rheumatoid arthritis after failed infliximab and/or etanercept therapy: experience with 18 patients [letter]. Joint Bone Spine 2004;71:601-3.
17. Hansen KE, Hildebrand JP, Genovese MC et al. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol 2004;31:1098-102.
18. Haraoui B, Keystone EC, Thorne JC et al. Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J Rheumatol 2004;31:2356-9.
19. Cohen G, Courvoisier N, Cohen JD, Zaltni S, Sany J, Combe B. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005;23:795-800.
20. Wick MC, Ernestam S, Lindblad S, Bratt J, Klareskog L, van Vollenhoven RF. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): Results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol 2005;34:353-8.
21. Bennett AN, Peterson P, Zain A, Grumley J, Panayi G, Kirkham B. Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure. Rheumatology 2005;44:1026-31.
22. Nikas SN, Voulgari PV, Alamanos Y et al. Efficacy and safety of switching from infliximab to adalimumab: A comparative controlled study. Ann Rheum Dis 2006;65:257-60.
23. Solau-Gervais E, Laxenaire N, Cortet B, Dubucquoi S, Duquesnoy B, Flipo RM. Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody. Rheumatology 2006;45:1121-4.
24. Iannone F, Trotta F, Montecucco C et al. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Ann Rheum Dis 2007;66:249-52.
25. Furst DE, Gaylis N, Bray V et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: The opposite study. Ann Rheum Dis 2007;66:893-9.
26. Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: Results from a large UK national cohort study. Arthritis Rheum 2007;56:13-20.
27. Gomez-Reino JJ, Carmona L. Switching TNF antagonists in patients with chronic arthritis: An observational study of 488 patients over a four-year period. Arthritis Res Ther 2006;8:R29.
28. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
29. Hyrich KL, Watson KD, Silman AJ, Symmons DP. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register. Rheumatology 2006;45:1558-65.
30. Kristensen LE, Saxne T, Nilsson JA, Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther 2006;8:R174.
31. Geborek P, Crnkic M, Petersson IF, Saxne T. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: Clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002;61:793-8.
32. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
33. DAS-SCORE. NL. http://www.das-score.nl/www.das-score.nl/index.html (24 April 2007, date last accessed).
34. Indices. In van Riel PLCM, Fransen J, Scott DL, eds. EULAR handbook of clinical assessment in rheumatoid arthritis. Alphen aan den Rijn: Van Zuiden Communications BV, 2004:33-40.
35. Ekdahl C, Eberhardt K, Andersson SI, Svensson B. Assessing disability in patients with rheumatoid arthritis. Use of a Swedish version of the Stanford Health Assessment Questionnaire. Scand J Rheumatol 1988;17:263-71.
36. van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40.
37. Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
38. Finckh A, Ciurea A, Brulhart L et al. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 2007;56:1417-23.
39. Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. Arthritis Rheum 2006;54:2784-92.
40. Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: The importance of disease duration. Arthritis Rheum 2000;43:22-9.
41. Zink A, Listing J, Kary S et al. Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 2005;64:1274-9.
42. Krishnan E, Fries JF. Measuring effectiveness of drugs in observational databanks: Promises and perils. Arthritis Res Ther 2004;6:41-4.
43. Haraoui B. Is there a rationale for switching from one anti-tumor necrosis factor agent to another? J Rheumatol 2004;31:1021-2.
44. Gulfe A, Geborek P, Saxne T. Response criteria for rheumatoid arthritis in clinical practice: How useful are they? Ann Rheum Dis 2005;64:1186-9.